Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
Open Access
- 1 September 2019
- journal article
- research article
- Published by Elsevier in JACC: Cardiooncology
- Vol. 1 (1) , 1-10
Abstract
No abstract availableKeywords
Funding Information
- Hamilton Health Sciences
This publication has 19 references indexed in Scilit:
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Prevention of Anthracycline-Induced CardiotoxicityJACC, 2014
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trialThe Lancet Oncology, 2013
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective StudyJournal of Cardiac Failure, 2009
- Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working GroupCurrent Oncology, 2008
- Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical TreatmentJournal of Clinical Oncology, 2005
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New EntityJournal of Clinical Oncology, 2005
- Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.Proceedings of the National Academy of Sciences, 1987